Source: Annual Congress 2012 - Anti-infective treatment and resistance in respiratory infections
Disease area: Paediatric lung diseases, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
I. Mitchell, B. Paes, A. Li, K. Lanctot (Hamilton, Canada). Factors associated with compliance with palivizumab treatment in the Canadian rSV evaluation study for synagis (CARESS) registry (32005-2011). Eur Respir J 2012; 40: Suppl. 56, 4371

Member's Comments

No comment yet.

Related content which might interest you: Risk factors that determine time to first RSV hospitalization in CARESS: The Canadian registry of palivizumab (2005-2011) Source: Annual Congress 2012 - Epidemiology of various respiratory diseases Year: 2012 RSV hospitalization in Down syndrome in the Canadian Registry of Synagis (CARESS) following prophylaxis (2006-2011) Source: Annual Congress 2012 - New insights into respiratory infections in children Year: 2012 CARESS: The Canadian registry of palivizumab (2005-2010) Source: Annual Congress 2011 - Paediatric respiratory infection: signs, symptoms and sequelae Year: 2011 An assessment of the use of palivizumab over 12 years from a Canadian Registry (CARESS). Source: International Congress 2019 – New insights into childhood infections: from viral bronchiolitis to bronchiolitis obliterans Year: 2019 RSV hospitalization in cystic fibrosis in the Canadian registry of palivizumab (CARESS) following prophylaxis (2005-2012) Source: Annual Congress 2013 –Cystic fibrosis: physiotherapy, exercise and lung function in adults and children Year: 2013 RSV hospitalization in infants with neuromuscular disease in the Canadian registry of palivizumab after prophylaxis (2005-2012) Source: Annual Congress 2013 –Paediatric respiratory epidemiology: bronchiolitis and asthma Year: 2013 Drug treatment in a German real-life COPD cohort (DACCORD) Source: International Congress 2015 – Treatment and control of respiratory disease Year: 2015 Changing incidence of pneumonia diagnosis in UK primary care from 2002-2017: Population-based cohort study Source: International Congress 2019 – Severe pneumonia: epidemiology, mechanisms and treatment Year: 2019 Respiratory syncytial virus (RSV) hospitalization in infants with congenital airway anomalies (CAA) in the canadian registry of palivizumab (CARESS) after prophylaxis (2005-2012) Source: International Congress 2014 – Paediatric epidemiology: new insights into primary ciliary dyskinesia, prematurity and bronchiolitis Year: 2014 Ten-year projected outcomes associated with increased use of triple therapies in UK patients with COPD using the COPD Health Outcome Policy and INtervention (CHOPIN) model Source: Virtual Congress 2021 – COPD pharmacology: from basic science to real-world data Year: 2021 Comorbidity and mortality in Swedish asthma patients 2006 – 2013 - An observational register study (PACEHR) Source: International Congress 2016 – Asthma management in primary care Year: 2016 The Northjutland COPD prevention study (NCPS) Source: Eur Respir J 2006; 28: Suppl. 50, 447s Year: 2006 Astro-Lab project: Assessment of the safety of long-acting beta agonists (LABAs) in asthma by combining health-care databases and direct patient follow-up: Description of the patient pattern in France and in the United-Kingdom (UK) Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease Year: 2013 National trends in utilization and outcomes of percutaneous coronary intervention (PCI) among patients with and without COPD in Spain (2001-2011) Source: International Congress 2014 – COPD: points to ponder Year: 2014 The Northjutland COPD follow-up prevention study (NCPS) Source: Annual Congress 2010 - Risk factors, prevalence and consequences of COPD Year: 2010 Real-world effects of lumacaftor/ivacaftor (LUM/IVA) in people with cystic fibrosis (pwCF): interim results of a long-term safety study using US CF Foundation Patient Registry (CFFPR) data Source: Virtual Congress 2021 – Clinical effects of CFTR modulatory therapy and lung inflammation in children with cystic fibrosis Year: 2021 Real-world effects of tezacaftor/ivacaftor (TEZ/IVA) in people with cystic fibrosis (pwCF): interim results of a long-term safety study using US CF Foundation Patient Registry (CFFPR) data Source: Virtual Congress 2021 – Clinical effects of CFTR modulatory therapy and lung inflammation in children with cystic fibrosis Year: 2021 Underlying clinical conditions and invasive pneumococcal disease (IPD) in adults in Spain (ODIN study, 2010-2012) Source: Annual Congress 2013 –Recent developments in pneumonia Year: 2013 Safety and effectiveness of indacaterol in Korean COPD patients: A post-marketing surveillance (PMS) study Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 Late Breaking Abstract - Early benefits in patient-reported outcomes (PROs) and physical activity (PA) in patients with severe eosinophilic asthma (SEA) treated with benralizumab: interim analysis of the imPROve Asthma study Source: Virtual Congress 2021 – Advances in asthma treatment Year: 2021